Mentari Therapeutics, Inc. Common Stock
MTRI
4 hedge funds and large institutions have $2.99M invested in Mentari Therapeutics, Inc. Common Stock in 2021 Q2 according to their latest regulatory filings, with 1 funds opening new positions, 1 increasing their positions, reducing their positions, and 4 closing their positions.
213% more capital inflows, than outflows
Capital inflows: $2.09M | Capital outflows: $667K
5.94% more ownership
Funds ownership: 5.8% → 11.74% (+5.9%)
43% less funds holding
Funds holding: 7 → 4 (-3)
75% less first-time investments, than exits
New positions opened: 1 | Existing positions closed: 4
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Armistice Capital
New York
|
+$2.03M |
| 2 |
Penserra Capital Management
Orinda,
California
|
+$61.9K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Hudson Bay Capital Management
Stamford,
Connecticut
|
-$531K |
| 2 |
Bank of America
Charlotte,
North Carolina
|
-$53K |
| 3 |
Morgan Stanley
New York
|
-$46.4K |
| 4 |
JP Morgan Chase
New York
|
-$36K |
| 5 |
Bank of Montreal
Toronto,
Ontario, Canada
|
-$1K |
MTRI Hedge Fund Activity: Q2 2021 in Review
4 of the 5,771 institutional investors tracked by Wall St. Rank reported a position in Mentari Therapeutics, Inc. Common Stock (MTRI) for Q2 2021, worth a combined $2.99M — up 93% from $1.55M a quarter earlier.
Sellers outnumbered buyers: 4 funds closed out of MTRI and 1 opened new positions — a net loss of 3 holders — while 0 trimmed existing stakes and 1 added.
The largest buyer was Armistice Capital, adding an estimated $2.03M. The largest seller was Hudson Bay Capital Management, exiting entirely with an estimated $531K sold.
- 4 institutional investors held Mentari Therapeutics, Inc. Common Stock (MTRI) as of Q2 2021, down from 7 in Q1 2021.
- Funds reported $2.99M of Mentari Therapeutics, Inc. Common Stock stock for Q2 2021, up 93% quarter-over-quarter.
- 1 fund opened new Mentari Therapeutics, Inc. Common Stock positions in Q2 2021 and 4 closed out, a net change of -3 holders.
- The largest Mentari Therapeutics, Inc. Common Stock buyer in Q2 2021 was Armistice Capital, an estimated $2.03M added.
- The largest Mentari Therapeutics, Inc. Common Stock seller in Q2 2021 was Hudson Bay Capital Management, an estimated $531K sold.
Based on aggregated 13F filings for Q2 2021.